Cargando…

Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM

BACKGROUND: This study aimed to evaluate the predictive and monitoring role of somatostatin receptor (SSTR) positron emission tomography-computed tomography (PET/CT) and clinical parameters in patients with neuroendocrine liver metastases (NELM) from pancreatic neuroendocrine tumors (pNET) receiving...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ingenerf, Maria, Karim, Homeira, Auernhammer, Christoph, Zacherl, Matthias, Wenter, Vera, Winkelmann, Michael, Ricke, Jens, Berger, Frank, Schmid-Tannwald, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690751/ https://www.ncbi.nlm.nih.gov/pubmed/38038419 http://dx.doi.org/10.2478/raon-2023-0055

Ejemplares similares

Evaluation of MRI in the diagnostic accuracy of extrahepatic metastases in neuroendocrine tumors in comparison with the reference standard somatostatin-receptor–PET/CT
por: Ingenerf, Maria, et al.
Publicado: (2023)

Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
por: Grawe, Freba, et al.
Publicado: (2023)

Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study
por: Katharina Ingenerf, Maria, et al.
Publicado: (2021)

(68)Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE)
por: Ingenerf, Maria, et al.
Publicado: (2021)

Diagnostic accuracy of SSR-PET/CT compared to histopathology in the identification of liver metastases from well-differentiated neuroendocrine tumors
por: Fabritius, M. P., et al.
Publicado: (2023)

Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters
por: Ingenerf, Maria, et al.
Publicado: (2022)

Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs
por: Grawe, Freba, et al.
Publicado: (2023)

Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
por: Thomas, Katharine, et al.
Publicado: (2020)

Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI
por: Arnfield, Evyn G., et al.
Publicado: (2023)

Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis
por: Arrivi, Giulia, et al.
Publicado: (2022)

Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT
por: Kunz, Wolfgang G., et al.
Publicado: (2018)

CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience
por: Sahu, Arvind, et al.
Publicado: (2019)

Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis
por: Lu, Yaoheng, et al.
Publicado: (2018)

Prognostic Value of Volume-Based Parameters Measured by SSTR PET/CT in Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
por: Hou, Jiale, et al.
Publicado: (2021)

Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol
por: Bongiovanni, Alberto, et al.
Publicado: (2020)

Long-Term Follow-Up of Significant Improvement After CAPTEM Treatment for Rare Adrenocorticotropin-Producing Cardiac Neuroendocrine Tumor
por: Lu, Lin, et al.
Publicado: (2019)

Dosimetry and optimal scan time of [(18)F]SiTATE-PET/CT in patients with neuroendocrine tumours
por: Beyer, Leonie, et al.
Publicado: (2021)

Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

The Value of SSTR2 Receptor-Targeted PET/CT in Proton Irradiation of Grade I Meningioma
por: Pelak, Maciej J., et al.
Publicado: (2021)

Anti-SSTR2 Antibody-drug Conjugate for Neuroendocrine Tumor Therapy
por: Si, Yingnan, et al.
Publicado: (2020)

mRNA expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 and its significance in pancreatic cancer
por: Shahbaz, Muhammad, et al.
Publicado: (2015)

Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry
por: Mizutani, Gou, et al.
Publicado: (2012)

Primary presentation and clinical course of pediatric and adolescent patients with differentiated thyroid carcinoma after radioiodine therapy
por: Burgard, Caroline, et al.
Publicado: (2023)

Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors
por: Koustoulidou, Sofia, et al.
Publicado: (2022)

The effect of strength and endurance training on SSTR2 and SSTR5 in patients with colorectal cancer
por: Zanjani, Farhad Safari, et al.
Publicado: (2019)

Expression of Somatostatin Receptor Subtypes (SSTR-1–SSTR-5) in Pediatric Hematological and Oncological Disorders
por: Harda, Kristof, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of (68)Ga DOTA-TATE PET/CT, (111)In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors
por: Froelich, Matthias Frank, et al.
Publicado: (2021)

Coexpression of human somatostatin receptor-2 (SSTR2) and SSTR3 modulates antiproliferative signaling and apoptosis
por: War, Sajad A, et al.
Publicado: (2012)

Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers—Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT
por: Werner, Rudolf A., et al.
Publicado: (2019)

Sarcoid-Like Reaction in Non-Hodgkin’s Lymphoma—A Diagnostic Challenge for Deauville Scoring on (18)F-FDG PET/CT Imaging
por: Winkelmann, Michael, et al.
Publicado: (2021)

Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?
por: Dalm, Simone U., et al.
Publicado: (2017)

Preoperative Imaging with [(18)F]-Fluorocholine PET/CT in Primary Hyperparathyroidism
por: Dekorsy, Franziska J., et al.
Publicado: (2022)

Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study
por: Linguanti, Flavia, et al.
Publicado: (2022)

Transformation of diffuse large B cell lymphoma into dendritic sarcoma under CAR T cell therapy detected on (18)F-FDG PET/CT
por: Winkelmann, Michael, et al.
Publicado: (2020)

Differences in the expression of SSTR1–5 in meningiomas and its therapeutic potential
por: Behling, Felix, et al.
Publicado: (2021)

Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors
por: Mehta, Shreya, et al.
Publicado: (2015)

Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [(18)F]SiTATE PET
por: Wängler, Carmen, et al.
Publicado: (2022)

The immunohistochemical expression of SSTR2A is an independent prognostic factor in meningioma
por: Fodi, Christina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rofv5orj9dgsjmfq61bu82ic41